In addition, it was reported that low HER-2 expression was a risk factor for poor prognosis in early-stage breast cancer patients, with a five year DFS of 84% (95% CI, 80%-88%) and 62% (95% CI, 48%-74%) in patients with HER-2 (1+) and HER-2 (2+) Fish (-), respectively.19,20 While in this study, only six patients had recurrence and metastasis in the enrolled 60 patients with low HER-2 expression. This evidence concerns the gene ERBB2 and breast cancer.